Clinical Cancer Research, Vol 2, Issue 10 1743-1749, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain

NI Obiri, SR Husain, W Debinski and RK Puri
Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. OBIRI@A1.CBER.FDA.GOV

Interleukin-13 (IL-13) is a cytokine produced primarily by activated T lymphocytes. It exerts a variety of effects on different cell types, including monocytes, B lymphocytes, mast cells, and keratinocytes. The effects of IL-13 on target cells are often similar to the effects of IL-4, which is another cytokine product of activated T lymphocytes. We recently described the expression of intermediate- to high-affinity receptors for IL-13 (IL-13R) on renal cell carcinoma (RCC) cells. In the present study, we examined the effect of IL-13 on the growth of RCC cells as measured by [3H]thymidine uptake and a clonogenic assay. In addition, we used an IL-4R-specific antibody to examine the specificity of IL-4R and IL-13R binding and function. We observed that IL-13 inhibited RCC cell proliferation by up to 50% and colony formation by up to 32% when compared with cells cultured in medium alone. A combination of IL-4 and IL-13 did not have an additive or synergistic effect on the growth of RCC cells. These cells expressed mRNA for IL-13 and secreted immunoreactive IL-13 protein in culture. The growth-inhibitory effects of IL-13 were specific, because they were not affected by antibodies to IL-4 or to the 140-kilodalton subunit of IL-4R. Furthermore, polyclonal antibodies to IL-4R failed to inhibit the binding of 125I-IL-13 to RCC cells. These results indicate that IL-13 has significant antiproliferative effects on human RCC cells, and the inhibition of IL-13 effects by anti-IL-4R antibody previously reported in lymphoid cells does not occur in RCC cells.

This article has been cited by other articles:

				T. Kleinrath, C. Gassner, P. Lackner, M. Thurnher, and R. Ramoner Interleukin-4 Promoter Polymorphisms: A Genetic Prognostic Factor for Survival in Metastatic Renal Cell Carcinoma J. Clin. Oncol., March 1, 2007; 25(7): 845 - 851. [Abstract] [Full Text] [PDF]

				M. Kioi, K. Kawakami, and R. K. Puri Analysis of Antitumor Activity of an Interleukin-13 (IL-13) Receptor-Targeted Cytotoxin Composed of IL-13 Antagonist and Pseudomonas Exotoxin Clin. Cancer Res., September 15, 2004; 10(18): 6231 - 6238. [Abstract] [Full Text] [PDF]

				H.-L. Ma, M. J. Whitters, B. A. Jacobson, D. D. Donaldson, M. Collins, and K. Dunussi-Joannopoulos Tumor cells secreting IL-13 but not IL-13R{alpha}2 fusion protein have reduced tumorigenicity in vivo Int. Immunol., July 1, 2004; 16(7): 1009 - 1017. [Abstract] [Full Text] [PDF]

				M. M. Mentink-Kane, A. W. Cheever, R. W. Thompson, D. M. Hari, N. B. Kabatereine, B. J. Vennervald, J. H. Ouma, J. K. Mwatha, F. M. Jones, D. D. Donaldson, et al. IL-13 receptor {alpha} 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis PNAS, January 13, 2004; 101(2): 586 - 590. [Abstract] [Full Text] [PDF]

				B. H. Joshi, K. Kawakami, P. Leland, and R. K. Puri Heterogeneity in Interleukin-13 Receptor Expression and Subunit Structure in Squamous Cell Carcinoma of Head and Neck: Differential Sensitivity to Chimeric Fusion Proteins Comprised of Interleukin-13 and a Mutated Form of Pseudomonas Exotoxin Clin. Cancer Res., June 1, 2002; 8(6): 1948 - 1956. [Abstract] [Full Text] [PDF]

				K. Kawakami, M. Kawakami, P. J. Snoy, S. R. Husain, and R. K. Puri In Vivo Overexpression of IL-13 Receptor {alpha}2 Chain Inhibits Tumorigenicity of Human Breast and Pancreatic Tumors in Immunodeficient Mice J. Exp. Med., December 17, 2001; 194(12): 1743 - 1754. [Abstract] [Full Text] [PDF]

				Y. Oshima, B. H. Joshi, and R. K. Puri Conversion of Interleukin-13 into a High Affinity Agonist by a Single Amino Acid Substitution J. Biol. Chem., May 5, 2000; 275(19): 14375 - 14380. [Abstract] [Full Text] [PDF]

				P. L. Orchansky, R. Kwan, F. Lee, and J. W. Schrader Characterization of the Cytoplasmic Domain of Interleukin-13 Receptor-alpha J. Biol. Chem., July 23, 1999; 274(30): 20818 - 20825. [Abstract] [Full Text] [PDF]

				N. I. Obiri, T. Murata, W. Debinski, and R. K. Puri Modulation of Interleukin (IL)-13 Binding and Signaling by the gamma c Chain of the IL-2 Receptor J. Biol. Chem., August 8, 1997; 272(32): 20251 - 20258. [Abstract] [Full Text] [PDF]

				Y. Oshima and R. K. Puri Characterization of a Powerful High Affinity Antagonist That Inhibits Biological Activities of Human Interleukin-13 J. Biol. Chem., April 27, 2001; 276(18): 15185 - 15191. [Abstract] [Full Text] [PDF]